05-Aug-2022 | D | Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company, in their meeting held on August 05, 2022, inter alia, approved/took on record the following :
Declaration of interim dividend of Rs. 7.35/- (at the rate of 735%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2022-2023. | 11-Aug-2022 | |
29-Jul-2021 | D | Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., July 29, 2021 inter alia, duly approved / took on record the following:
Declaration of interim dividend of Rs. 6.01 (at the rate of 601%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2021-2022; | 05-Aug-2021 | |
04-Aug-2020 | D | Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 04, 2020, inter alia, duly approved / took on record the following:
- Declaration of Interim Dividend of Rs 5.50/- (at the rate of 550%) on each fully paid-up equity share of Re.1/- for the Financial Year 2020-21.
| 13-Aug-2020 | |
11-Mar-2020 | D | Eris Lifesciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on March 11, 2020 duly approved the declaration of Interim Dividend of Rs. 2.87/- (at the rate of 287%) on each fully paid-up equity share of Re. 1/- for the Financial Year 2019-20. | 19-Mar-2020 | |
19-Apr-2024 | BC | Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Monday | 22-Apr-2024 | |
14-Mar-2024 | BC | Trading Members of the Exchange are hereby informed that the under mentioned new securities issued by Eris Lifesciences Limited on private placement basis is listed and admitted to dealings on the BS | 14-Mar-2024 | |
14-Mar-2024 | BC | Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in its meet | 14-Mar-2024 | |
06-Feb-2024 | BC | Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the standalone and consolidated unaudited | 13-Feb-2024 | |
08-Feb-2024 | BC | UTI Mutual Fund | 07-Feb-2024 | |
Announcement Date05-Aug-2022
Ex Dividend Date11-Aug-2022
Dividend(%)735
Announcement Date29-Jul-2021
Ex Dividend Date05-Aug-2021
Dividend(%)601
Announcement Date04-Aug-2020
Ex Dividend Date13-Aug-2020
Dividend(%)550
Announcement Date11-Mar-2020
Ex Dividend Date19-Mar-2020
Dividend(%)287
No Bonus has been declared by ERIS
No Split has been declared by ERIS
RightsNo Rights has been declared by ERIS
Book Closure
22-Apr-2024 | - | Trading Members of the Exchange are hereby informed that the further new securities issued by the under mentioned companies are listed and admitted for trading on the Exchange with effect from Monday |
14-Mar-2024 | - | Trading Members of the Exchange are hereby informed that the under mentioned new securities issued by Eris Lifesciences Limited on private placement basis is listed and admitted to dealings on the BS |
14-Mar-2024 | - | Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in its meet |
13-Feb-2024 | - | Eris Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2024 inter alia to consider and approve the standalone and consolidated unaudited |
07-Feb-2024 | - | UTI Mutual Fund |